585 related articles for article (PubMed ID: 19691094)
1. Time to disease recurrence in basal-type breast cancers: effects of tumor size and lymph node status.
Dent R; Hanna WM; Trudeau M; Rawlinson E; Sun P; Narod SA
Cancer; 2009 Nov; 115(21):4917-23. PubMed ID: 19691094
[TBL] [Abstract][Full Text] [Related]
2. Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Collins LC; Martyniak A; Kandel MJ; Stadler ZK; Masciari S; Miron A; Richardson AL; Schnitt SJ; Garber JE
Am J Surg Pathol; 2009 Jul; 33(7):1093-7. PubMed ID: 19390427
[TBL] [Abstract][Full Text] [Related]
3. Molecular markers for prognosis after isolated postmastectomy chest wall recurrence.
Haffty BG; Hauser A; Choi DH; Parisot N; Rimm D; King B; Carter D
Cancer; 2004 Jan; 100(2):252-63. PubMed ID: 14716758
[TBL] [Abstract][Full Text] [Related]
4. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation.
Rakha EA; Putti TC; Abd El-Rehim DM; Paish C; Green AR; Powe DG; Lee AH; Robertson JF; Ellis IO
J Pathol; 2006 Mar; 208(4):495-506. PubMed ID: 16429394
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
6. Patterns of recurrence in the basal and non-basal subtypes of triple-negative breast cancers.
Nofech-Mozes S; Trudeau M; Kahn HK; Dent R; Rawlinson E; Sun P; Narod SA; Hanna WM
Breast Cancer Res Treat; 2009 Nov; 118(1):131-7. PubMed ID: 19189211
[TBL] [Abstract][Full Text] [Related]
7. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
8. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
[TBL] [Abstract][Full Text] [Related]
9. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel.
Millar EK; Graham PH; O'Toole SA; McNeil CM; Browne L; Morey AL; Eggleton S; Beretov J; Theocharous C; Capp A; Nasser E; Kearsley JH; Delaney G; Papadatos G; Fox C; Sutherland RL
J Clin Oncol; 2009 Oct; 27(28):4701-8. PubMed ID: 19720911
[TBL] [Abstract][Full Text] [Related]
10. Prognostic markers in node-negative breast cancer: a prospective study.
Kute TE; Russell GB; Zbieranski N; Long R; Johnston S; Williams H; Stackhouse C; Wilkins L; Evans I; Berry P; Rimmer K; Tucker E
Cytometry B Clin Cytom; 2004 May; 59(1):24-31. PubMed ID: 15108167
[TBL] [Abstract][Full Text] [Related]
11. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.
Kyndi M; Sørensen FB; Knudsen H; Overgaard M; Nielsen HM; Overgaard J;
J Clin Oncol; 2008 Mar; 26(9):1419-26. PubMed ID: 18285604
[TBL] [Abstract][Full Text] [Related]
12. Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance.
Rakha EA; El-Rehim DA; Paish C; Green AR; Lee AH; Robertson JF; Blamey RW; Macmillan D; Ellis IO
Eur J Cancer; 2006 Dec; 42(18):3149-56. PubMed ID: 17055256
[TBL] [Abstract][Full Text] [Related]
13. Bone metastasis is strongly associated with estrogen receptor-positive/progesterone receptor-negative breast carcinomas.
Wei B; Wang J; Bourne P; Yang Q; Hicks D; Bu H; Tang P
Hum Pathol; 2008 Dec; 39(12):1809-15. PubMed ID: 18715613
[TBL] [Abstract][Full Text] [Related]
14. Local recurrence after mastectomy for breast cancer: analysis of clinicopathological, biological and prognostic characteristics.
Carreño G; Del Casar JM; Corte MD; González LO; Bongera M; Merino AM; Juan G; Obregón R; Martínez E; Vizoso FJ
Breast Cancer Res Treat; 2007 Mar; 102(1):61-73. PubMed ID: 16850244
[TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
16. Basal phenotype: a powerful prognostic factor in small screen-detected invasive breast cancer with long-term follow-up.
Evans AJ; Rakha EA; Pinder SE; Green AR; Paish C; Ellis IO
J Med Screen; 2007; 14(4):210-4. PubMed ID: 18078567
[TBL] [Abstract][Full Text] [Related]
17. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
Keshgegian AA; Cnaan A
Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
[TBL] [Abstract][Full Text] [Related]
18. Prognostic relevance of basal cytokeratin expression in operable breast cancer.
Potemski P; Kusinska R; Watala C; Pluciennik E; Bednarek AK; Kordek R
Oncology; 2005; 69(6):478-85. PubMed ID: 16410686
[TBL] [Abstract][Full Text] [Related]
19. Recurrence in breast cancer. Analysis with frailty model.
Gohari MR; Mahmoudi M; Mohammed K; Pasha E; Khodabakhshi R
Saudi Med J; 2006 Aug; 27(8):1187-93. PubMed ID: 16883450
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic features and five years survival analysis in molecular subtypes of breast cancer.
Zaha DC; Lazăr E; Lăzureanu C
Rom J Morphol Embryol; 2010; 51(1):85-9. PubMed ID: 20191125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
